erlotinib hydrochloride has been researched along with Bone Neoplasms in 28 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (25.00) | 29.6817 |
2010's | 19 (67.86) | 24.3611 |
2020's | 2 (7.14) | 2.80 |
Authors | Studies |
---|---|
Harada, H; Katagiri, H; Miyagi, M; Mori, K; Murakami, H; Murata, H; Takahashi, M; Takahashi, T; Wasa, J | 1 |
He, M; Ji, XL | 1 |
Bandyopadhyay, A; Favours, E; Ghilu, S; Guttridge, D; Hirotani, K; Houghton, PJ; Kurmashev, D; Kurmasheva, RT; London, C; Michalek, J; Phelps, DA; Pozo, VD; Trevino, A; Zhang, L | 1 |
Borghaei, H; Camidge, R; Deal, A; Kavanagh, B; Kirpalani, P; Lee, C; Morris, D; Pecot, CV; Pennell, N; Stevenson, J; Stinchcombe, T; Villaruz, L; Weiss, J; West, J; Zagar, T | 1 |
Asklund, T; Henriksson, R; Riklund, K; Sandström, M; Shahidi, S | 1 |
Ma, D; Mathur, G | 1 |
Kau, HC; Tsai, CC | 1 |
Cai, XH; Feng, CJ; Huang, CY; Liu, XK; Lu, Y; Wang, L; Wang, Y; Wang, YS; Xu, Y; Yao, WX; Yu, P; Zhou, J; Zhu, WJ | 1 |
Bell, D; Garber, ST; Janku, F; Khoury, L; McCutcheon, IE; Schomer, DF | 1 |
Bachariou, A; Chasapi, V; Papadopoulos, R | 1 |
Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD | 1 |
Alexandrescu, DT; Dasanu, CA; Kauffman, CL | 1 |
Lind, JS; Postmus, PE; Smit, EF | 1 |
Ahn, JS; Ahn, MJ; Ahn, YC; Kim, JA; Lee, J; Lee, S; Park, HC; Park, K; Park, YH; Sun, JM | 1 |
Chang, CC; Chang, HJ; Chi, KH; Hsieh, YS; Hsu, PS; Jiang, JS; Kao, SJ; Tsang, YW; Yeh, YW | 1 |
Cui, CX; Hao, XZ; Li, JL; Shi, YK; Wang, B; Wang, HY; Wang, Y; Zhang, XR; Zhao, LD | 1 |
Fujimoto-Ohuchi, K; Furugaki, K; Iwai, T; Kondoh, K; Mori, K; Moriya, Y; Yanagisawa, M; Yorozu, K | 1 |
Bertucci, F; Chetaille, B; Guiramand, J; Launay, SG; Medina, F; Moureau-Zabotto, L; Nazarian, S; Perrot, D | 1 |
Eshuis, SA; Gemmel, F; Gemmel, P; van Vollenhoven, F | 1 |
Knap, MM; Madsen, HH; Meldgaard, P; Nexo, E; Sorensen, BS; Weber, B | 1 |
Gabr, AG; Goto, H; Hanibuchi, M; Kakiuchi, S; Kuramoto, T; Moriya, Y; Nishioka, Y; Ogawa, H; Saijo, A; Sakaguchi, S; Sone, S; Suzuki, M; Trung, VT | 1 |
Endo, M; Harada, H; Inomata, M; Kenmotsu, H; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
Antoine, M; Blons, H; Buisine, MP; Cadranel, J; Chetaille, B; Chouaid, C; Coudert, B; Daniel, C; Danton, G; De Fraipont, F; Faller, M; Foucher, P; Lacroix, L; Longchampt, E; Mauguen, A; Michiels, S; Morin, F; Pignon, JP; Poulot, V; Quoix, E; Solassol, J; Urban, T; Westeel, V; Wislez, M; Zalcman, G | 1 |
Choong, NW; Davies, GC; Dietrich, S; Husain, AN; Lipkowitz, S; Ma, PC; Nallasura, V; Salgia, R; Seiwert, TY; Tretiakova, MS | 1 |
Fregoni, V; Pavesi, L; Ponchio, L; Prada, GA; Sagrada, P; Zambelli, A | 1 |
Epstein, RJ; Leung, TW | 1 |
Lazzari, G; Lovecchio, M; Palazzo, C; Silvano, G | 1 |
2 review(s) available for erlotinib hydrochloride and Bone Neoplasms
Article | Year |
---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chordoma; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Male; Molecular Targeted Therapy; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Treatment Outcome | 2011 |
4 trial(s) available for erlotinib hydrochloride and Bone Neoplasms
Article | Year |
---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Radiosurgery; Survival Rate | 2019 |
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Osteosarcoma; Quinazolines; Rhabdomyosarcoma; Temozolomide | 2008 |
Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Heart Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
23 other study(ies) available for erlotinib hydrochloride and Bone Neoplasms
Article | Year |
---|---|
Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cantharidin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Child; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Nude; Osteosarcoma; Phosphorylation; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2019 |
Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Broadly Neutralizing Antibodies; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Humans; Mice; Mice, SCID; Receptor, ErbB-3; Sarcoma, Ewing; Xenograft Model Antitumor Assays | 2018 |
Durable stabilization of three chordoma cases by bevacizumab and erlotinib.
Topics: Adult; Antibodies, Monoclonal, Humanized; Bevacizumab; Bone Neoplasms; Chordoma; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Quinazolines; Sacrum; Skull Neoplasms; Treatment Outcome | 2014 |
Coexistence of tyrosine kinase inhibitor-sensitizing and resistant EGFR mutations in an untreated lung adenocarcinoma patient and response to erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Palliative Care; Protein Kinase Inhibitors; Quinazolines | 2014 |
Erlotinib-related keratopathy in a patient underwent laser in situ keratomileusis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Bone Neoplasms; Corneal Diseases; ErbB Receptors; Erlotinib Hydrochloride; Humans; Keratomileusis, Laser In Situ; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Spinal Neoplasms | 2016 |
Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diphosphonates; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pamidronate; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2016 |
Metastatic Adenoid Cystic Carcinoma Mimicking Butterfly Glioblastoma: A Rare Presentation in the Splenium of the Corpus Callosum.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Adenoid Cystic; Chemotherapy, Adjuvant; Corpus Callosum; Cranial Irradiation; Decompression, Surgical; Diagnosis, Differential; Erlotinib Hydrochloride; Glioblastoma; Humans; Kidney Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Metastasectomy; Parotid Neoplasms; Radiotherapy, Adjuvant | 2016 |
Trichomegaly induced by erlotinib.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Humans; Hypertrichosis; Lung Neoplasms; Lymphatic Metastasis; Protein Kinase Inhibitors; Quinazolines | 2008 |
Persistent hair growth during treatment with the EGFR inhibitor erlotinib.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Hair; Hair Color; Humans; Hypertrichosis; Lung Neoplasms; Neoplasm Proteins; Paronychia; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2009 |
Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report.
Topics: Adenocarcinoma; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Osteoblasts; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.
Topics: Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2011 |
[Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2011 |
Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292.
Topics: Animals; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Mice; Neoplasm Invasiveness; Osteoblasts; Osteolysis; Protein Kinase Inhibitors; Quinazolines | 2011 |
Osteoblastic healing response: discordant PET/CT findings.
Topics: Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Multimodal Imaging; Osteoblasts; Positron-Emission Tomography; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib.
Topics: Adenocarcinoma; Adult; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression.
Topics: Animals; Bone Neoplasms; Carcinoma, Small Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Osteoblasts; Osteoclasts; Protein Kinase Inhibitors; Quinazolines; RANK Ligand | 2012 |
Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer.
Topics: Adult; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Treatment Outcome | 2011 |
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Risk Factors; Survival Rate | 2012 |
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Meningeal Neoplasms; Mutation; Quinazolines; Ribs; Treatment Failure | 2006 |
Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cesarean Section; Disease Progression; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Infant, Newborn; Lung Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Quinazolines; Withholding Treatment | 2008 |
Tumor resensitization to erlotinib following brief substitution of cetuximab.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Neoplasms; Cetuximab; Deoxycytidine; Drug Eruptions; Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Acute and fatal diarrhoea after erlotinib plus abdominal palliative hypofractionated radiotherapy in a metastatic non-small cell lung cancer patient: a case report.
Topics: Acute Disease; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Pain Management; Palliative Care; Quinazolines; Radiotherapy; Shock; Spinal Cord Compression | 2008 |